Agrylin (anagrelide HCL)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved December 1998

Specific Treatments:

Cardiology

Therapeutic Areas

General Information

Agrylin Capsules are indicated for the treatment of patients with Essential Thrombocythemia to reduce the elevated platelet count and the risk of thrombosis.

Agrylin Capsules are also indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.

Side Effects

These include the following: congestive heart failure, myocardial infarction, cardiomyopathy, cardiomegaly, complete heart block, atrial fibrillation, cerebrovascular accident, pericarditis, pulmonary infiltrates, pulmonary fibrosis, pulmonary hypertension, pancreatitis, gastric/duodenal ulceration, and seizure.